Explore our free mid-revenue cycle articles and webinars here.

Ask a Rev Cycle Expert: New COVID Payment (NCTAP) for Remdesivir?

Question:

With the renewal of the public health emergency (PHE), does the additional 20% on Medicare payments for New COVID-19 Payment (NCTAP) for remdesivir continue?

Answer:

Yes, the additional 20% add-on payment will continue through the end of the PHE. As long as the U.S. Food & Drug Administration (FDA) does not revoke the emergency use authorization (EUA), the drug will receive the 20% NCTAP until the end of the PHE has been declared.

Disclaimer: This information was current at the time of its publishing and is designed to provide accurate information in regard to the subject matter covered. Vitalware does not accept any responsibility or liability with regard to any errors, omissions, misuses, or misinterpretation by the reader. It is not intended to take the place of either the written policies or regulations. We encourage you to review the specific regulations and other interpretive materials as necessary. All CPT® codes are trademarked by the American Medical Association (AMA) and all revenue codes are copyrighted by the American Hospital Association (AHA).